VELPACLEAR combines two direct-acting antiviral agents that work synergistically to block the replication of hepatitis C virus (HCV) at different stages.
Sofosbuvir inhibits the NS5B RNA-dependent RNA polymerase, essential for viral replication.
Velpatasvir targets the NS5A protein, disrupting viral assembly.
This combination is effective across all six major HCV genotypes and helps achieve a sustained virologic response (SVR) in 12 weeks.
Recommended for:
Adults diagnosed with chronic hepatitis C (genotypes 1–6)
Patients with or without compensated cirrhosis
Individuals previously untreated or with treatment failure from older therapies
Those seeking interferon-free therapy with minimal side effects
VELPACLEAR is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adult patients, including those with compensated cirrhosis. It is suitable as a standalone oral regimen.
One tablet should be taken orally once daily, with or without food. Treatment duration is usually 12 weeks, depending on the patient’s genotype, liver condition, and previous treatment history. Consultation with a hepatologist or infectious disease specialist is advised for tailored therapy.
Contraindications:
Known hypersensitivity to sofosbuvir, velpatasvir, or any excipients
Co-administration with strong inducers of P-gp or CYP (e.g. rifampicin, carbamazepine)
Severe hepatic impairment without medical supervision
Side Effects:
Headache
Fatigue
Nausea
Insomnia
Anaemia (rare)
Elevated liver enzymes (requires monitoring)
